Abstract
Simple SummaryThe estrogen and androgen receptors (ER, AR) are key oncogenic drivers and therapeutic targets in breast and prostate cancer, respectively. These receptors bind to DNA and regulate gene expression but emerging evidence indicates that they also play important roles in controlling the process of mRNA translation, which dictates cellular protein production. Here, we review the mechanisms by which abnormal activities of ER and AR can dysregulate mRNA translation in breast and prostate cancer cells. Specifically, we explore how the intricate cellular signalling pathways that keep mRNA translation in check are perturbed by aberrant ER and AR signalling, which can lead to enhanced cancer cell growth. We also discuss the potential of targeting mRNA translation as a strategy to treat patients with breast and prostate cancer.Breast and prostate cancer are the second and third leading causes of death amongst all cancer types, respectively. Pathogenesis of these malignancies is characterised by dysregulation of sex hormone signalling pathways, mediated by the estrogen receptor-α (ER) in breast cancer and androgen receptor (AR) in prostate cancer. ER and AR are transcription factors whose aberrant function drives oncogenic transcriptional programs to promote cancer growth and progression. While ER/AR are known to stimulate cell growth and survival by modulating gene transcription, emerging findings indicate that their effects in neoplasia are also mediated by dysregulation of protein synthesis (i.e., mRNA translation). This suggests that ER/AR can coordinately perturb both transcriptional and translational programs, resulting in the establishment of proteomes that promote malignancy. In this review, we will discuss relatively understudied aspects of ER and AR activity in regulating protein synthesis as well as the potential of targeting mRNA translation in breast and prostate cancer.
Highlights
Simple Summary: The estrogen and androgen receptors (ER, AR) are key oncogenic drivers and therapeutic targets in breast and prostate cancer, respectively
Mutation of genes implicated in translation regulation and perturbation of translational programs appears to be a common feature of breast cancers (BC)/prostate cancers (PC), which provides a strong rationale for targeting translational machinery in these diseases
AR-low PC cells exhibited higher sensitivity to 4EBP1 over-expression as compared to corresponding models with high levels of AR [30]. These findings suggest that the absence of AR can promote protein synthesis, and that the effects of AR on translation may be mediated via regulation of 4EBP1/eIF4F
Summary
2. Dysregulation of Translation Is a Common Feature of Cancer of mRNAs can be broadly divided into four steps: initiation, elongation, 2.1. Translation Initiation termination and ribosome recycling [12]. The initiation and elongation steps of translation. Translation of mRNAs can be broadly divided into four steps: initiation, elongation, are thought and to be the most highly regulated andand have steps been ofstudied most intentermination ribosome recycling [12]. Dysregulation of translation in cancer, which of alterations in are thought to be the most highly regulated and have beenoccurs studiedbecause most intensively the levels or the activity of the components of translational [14], canlevimpact any [13]. Dysregulation of translation in cancer, which occurs becausemachinery of alterations in the ofels these steps. The activity of the components of translational machinery [14], can impact any of these steps
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
